Stage IV Pancreatic Cancer Clinical Trial
Official title:
A Phase II Study of the Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
Verified date | June 2014 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This phase II trial is studying how well RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) works in treating patients with previously treated metastatic pancreatic cancer. RO4929097 may stop the growth of tumor cells by blocking some enzymes needed for cell growth.
Status | Completed |
Enrollment | 18 |
Est. completion date | May 2014 |
Est. primary completion date | July 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed metastatic pancreatic adenocarcinoma - Not amenable to potentially curative surgical resection - At least 1 prior regimen of chemotherapy, preferably gemcitabine-based, for metastatic disease - Evidence of disease progression - Measurable disease defined as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral CT scan - Available archived tumor tissue (baseline core biopsies or surgical tumor blocks) - No diagnosis by fine-needle aspiration only - No known brain metastases - Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 (Karnofsky 70-100%) - White blood cell count (WBC) = 3,000/mm³ - Absolute neutrophil count (ANC) = 1,500/mm³ - Platelet count = 100,000/mm³ - Hemoglobin = 9 g/dL - Total bilirubin normal - Aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases present) - Creatinine normal OR creatinine clearance = 60 mL/min - Willingness to undergo 2 tumor biopsies, if required - Fertile patients must use 2 forms of contraception (i.e., barrier contraception and one other method of contraception) = 4 weeks prior to, during, and for = 12 months after completion of therapy - Negative pregnancy test - Not pregnant or nursing - Able to swallow pills - No patients with malabsorption syndrome or other condition that would interfere with intestinal absorption - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma secretase inhibitor RO4929097 - Not serologically positive for hepatitis A, B, or C - No history of liver disease, other forms of hepatitis, or cirrhosis - No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia, or hypokalemia despite adequate electrolyte supplementation - No uncontrolled intercurrent illness including, but not limited to, any of the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable angina pectoris - Cardiac arrhythmia other than chronic, stable atrial fibrillation - Psychiatric illness/social situations that would limit compliance with study requirements - No baseline QTcF > 450 msec (male) or QTcF > 470 msec (female) - No other malignancy within the past 5 years except curatively treated basal cell carcinoma of the skin or carcinoma in-situ of the uterine cervix - No combination antiretroviral therapy for HIV-positive patients - Recovered to < Common Toxicity Criteria for Adverse Effects (NCI CTCAE) grade 2 toxicities from prior therapy - More than 3 weeks since prior chemotherapy for metastatic disease (6 weeks for carmustine or mitomycin C) - At least 4 weeks since prior radiotherapy - Concurrent low-molecular weight heparin (LMWH) or full-dose coumadin allowed - International normalized ratio (INR) must be monitored as clinically indicated - No other concurrent investigational agents - No concurrent strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers, including the following: - Strong inhibitors: Amiodarone, erythromycin, clarithromycin, grapefruit juice, isoniazid, ketoconazole, itraconazole, or nefazodone - Patients taken off strong inhibitors allowed provided they have = 1-week washout period - Strong inducers: Carbamazepine, pentobarbital, phenobarbital, phenytoin, Rifabutin, Rifampin, or St. John wort - Patients taken off strong inducers allowed provided they have = 2-week washout period - No concurrent antiarrhythmics or other medications known to prolong QTc |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Cancer Center - Anschutz Cancer Pavilion | Aurora | Colorado |
United States | Johns Hopkins University/Sidney Kimmel Cancer Center | Baltimore | Maryland |
United States | University of Colorado | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Survival Rate | The primary endpoint of the study was 6-month survival. The proportion of successes was estimated by the number of successes divided by the total number of evaluable patients. | 6 months | No |
Secondary | Survival | Survival was estimated using the Kaplan-Meier (1958) method. | From registration to death due to any cause, assessed up to 2 years | No |
Secondary | Time to Disease Progression | Eighteen patients were evaluable for the time to disease progression endpoint. | From registration to documentation of disease progression, assessed up to 2 years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495896 -
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT02005315 -
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01453153 -
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01064622 -
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00095966 -
Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02178436 -
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT01647828 -
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Terminated |
NCT01555489 -
Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca
|
Phase 2 | |
Terminated |
NCT01233505 -
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT00735917 -
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02896907 -
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery
|
Early Phase 1 | |
Completed |
NCT02307539 -
Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer
|
N/A | |
Completed |
NCT02050178 -
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT01488552 -
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01222689 -
Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT00397787 -
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
|
Phase 2 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT01893801 -
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
|
Phase 1/Phase 2 |